



Good Clinical Practice & Pharmacovigilance Symposium

FEBRUARY 13-15, 2024



Version 15 – Updated February 11, 2024

For files and resources, please visit

[The Event Page on SBIAevents.com](https://www.sbiaevents.com)

[Add Event to Your Calendar](#)

AGENDA

All times are Eastern (UTC-5)

[View Start Time on World Clock](#)

DAY ONE: Tuesday, February 13, 2024

8:30 – 8:40

Welcome

Brenda Stodart, PharmD, MS, BCGP, RAC

Captain | United States Public Health Service (USPHS)

Director | Small Business, and Industry Assistance (SBIA)

Division of Drug Information (DDI) Office of Communications (OCOMM)

Center for Drug Evaluation and Research (CDER) | FDA

8:40 – 8:55

Opening Remarks & Keynote Address

Dr. Patrizia Cavazzoni

Director

CDER / FDA

Your SBIA Host for Day One

Forest "Ray" Ford, PharmD, BCPS

CAPT | USPHS

Pharmacist | DDI | OCOMM | CDER

9:00 – 9:55

Session 1 – Good Clinical Practice (GCP) Harmonization: Updates to ICH E6(R3)

Moderator: **Kassa Ayalew, MD, MPH** | OSI | FDA

- Discuss the basis for updates, status, and timeline
- Provide an overview of draft GCP principles and Annex 1 guideline, including a highlight of areas that have been updated/changed from ICH E6 (R2)
- Discuss plans for Annex 2

Leigh Marcus, MD

Senior Physician | OSI | FDA

Hocine Abid, MD, MBA

National Manager | ROEB | HC

Andrew Fisher, MSc

Lead Senior GCP Inspector | MHRA

10:00 – 10:20: BREAK

DAY ONE: Tuesday, February 13, 2024

10:25 – 11:05

Session 2- Technology in Clinical Trials – Digital Health Technology (DHT)

Moderator: **Debbi Fox, BSc** | *Compliance Specialist*
ROEB | HC

Discuss important considerations for sponsor for the appropriate management, traceability and security for data derived from DHTs and other computerized systems used to manage the study data, including, but not limited to, considerations for the following:

- Audit trails and metadata maintenance, review, and retention
- Data corrections
- Data transfer, exchange, and migration
- User access management

Elena Boley, MD, MBA
Senior Physician | OSI | FDA

Debbi Fox, BSc
Compliance Specialist | ROEB | HC

Mandy Budwal-Jagait, MSc
Head of GCP and Lead Senior GCP Inspector | MHRA

11:10 – 12:05

Session 3 – Clinical Trials with Decentralized Elements and GCP Inspections

Moderator: **Karen Bleich, MD** | *Lead Physician* | OMP | FDA

- Discuss clinical trials with decentralized elements
- Discuss regulatory challenges and GCP compliance of clinical studies with innovative features
- Highlight inspection case studies of clinical trials with decentralized elements and innovative features

Lee Pai-Scherf, MD
Senior Medical Officer | OSI | FDA

Alicja Kasina, MSc
Senior Regulatory Advisor | ROEB | HC

Hayley Dixey, BSc
Lead Senior GCP Inspector | MHRA

12:10 – 1:10 PM: LUNCH BREAK

DAY ONE: Tuesday, February 13, 2024

1:15 – 2:15

Session 4 – Good Data Governance Practice Updates

Moderator: **Shila Rastegar, MSc** | *Compliance Specialist*
ROEB | HC

- Discuss the importance of good data governance practices in the conduct of a clinical trial
- Provide updates to ICH E6R3 related to data governance, including updates to sponsor and investigator responsibilities
- Discuss the risk proportionate management of computerized systems and data governance processes.
- Provide case examples to illustrate the importance the new draft recommendations in E6R3 related to data governance

Cheryl Grandinetti, PharmD
Pharmacologist | OSI | FDA

Shila Rastegar, MSc
Compliance Specialist | ROEB | HC

Andrew Fisher, MSc
Lead Senior GCP Inspector | MHRA

2:20 – 2:35: BREAK

2:40 – 3:40

Panel Discussion (Q&A)

Moderator: **Regina Zopf, MD**
Senior Medical Officer | OSI | FDA

3:45 – 3:55

Wrap-Up & Closing Remarks

Hocine Abid, MD, MBA
National Manager | ROEB | HC

3:55: ADJOURN DAY ONE

4:00 – 5:00 PM: NETWORKING OPPORTUNITY

Onsite attendees are invited to gather at THE HOTEL's Lobby Bar to continue the conversation with fellow attendees.



DAY TWO: Wednesday, February 14, 2024

8:30 – 8:40

Day Two Welcome

Forest "Ray" Ford, PharmD, BCPS
Captain | United States Public Health Service (USPHS)
Pharmacist | Small Business and Industry Assistance (SBIA)
 Division of Drug Information (DDI) Office of Communications (OCOMM)
 Center for Drug Evaluation and Research (CDER)

8:40 – 8:55

Opening Remarks & Keynote Address

James Pound, BSc, CChem
Deputy Director | Standards & Compliance
 MHRA

9:00 – 10:00

Session 1- Sponsor Oversight in Clinical Trials

Moderator: **Adil Nashed, BVSc, DHMS** | *Compliance Specialist*
 ROEB | HC

- Discuss sponsor role and oversight responsibilities in global clinical trials, including those trials incorporating novel designs, operational approaches, and data sources
- Highlight the expanding use of 3rd parties and service providers performing clinical trial-related activities
- Discuss risk proportionate sponsor oversight measures that focus on what is important to ensure reliable trial results, trial participant's safety, and appropriate decision making

Adil Nashed, BVSc., DHMS
Compliance Specialist | ROEB | HC

Barbara Wright, BA
Foreign Cadre Director | Foreign BIMO Cadre
 FDA | ORA

Jason Wakelin-Smith, BSc
Expert GCP Inspector and
Head of the Compliance Expert Circle | MHRA

10:00 – 10:20: BREAK

10:25 – 11:25

Session 2 – Clinical Trials Post-Pandemic – Positive Disruption to Established Ways of Working?

Moderator: **Iram Hassan, PhD** | *LCDR | USPHS | OSI | GCOB |*
 FDA

- Discuss changes in the conduct of clinical trials and inspection activities post-pandemic
- Discuss the adoption of regulatory flexibilities into routine practice
- Insights from inspections on new approaches to clinical trial conduct

Jason Wakelin-Smith, BSc
Expert GCP Inspector and
Head of the Compliance Expert Circle | MHRA

Jennifer Evans, BSc
Compliance Specialist | ROEB | HC

Richard Berning
Foreign BIMO Cadre | ORA | FDA

DAY TWO: Wednesday, February 14, 2024

11:25 – 12:15

Session 3 - The Future of GCP Inspections

Moderator: **Kassa Ayalew, MD, MPH** | OSI | FDA

- Discuss experiences and lessons learned during the pandemic regarding inspections supporting marketing application review
- Discuss the development of the remote regulatory assessments (RRA)/remote inspections (RI) tool
- Discuss current and future use of RRAs/RIs

Jenn Sellers, MD, PhD

Branch Chief | OSI | FDA

Jennifer Adams, MPH

LCDR | USPHS | *Foreign Cadre Director* | ORA | FDA

Rachel Mead, BSc

Senior GCP Inspector | MHRA

12:15 – 1:15: LUNCH BREAK

1:20 – 2:05

Session 4- Agency Updates: Policies, Guidances, and Initiatives

Moderator: **Emily Gebbia, JD** | OSI | FDA

Stephen Vinter, BSc, CChem

Head of Compliance Team 1 | MHRA

Emily Gebbia, JD

Associate Director of Regulatory Development | OSI | FDA

Hocine Abid, MD, MBA

National Manager | ROEB | HC

2:10 – 2:40

Session 5 – Collaboration Between Agencies and Future Expectations

Moderator: **Mandy Budwal-Jagait, MSc** | *Head of GCP and Lead Senior GCP Inspector* | MHRA

LaKisha Williams, MSN

CDR | USPHS | FDA | OSI | DCCE

Reza Salehzadeh-Asl, MSc

National Supervisor | ROEB | HC

Mandy Budwal-Jagait, MSc

Head of GCP and Lead Senior GCP Inspector, MHRA

2:45 – 3:00: BREAK

3:00 – 4:00

Panel Discussion (Q&A)

Moderator: **Ryan Raffaelli, MD** | OSI | GCOB | FDA

4:00 – 4:10

Wrap-up and Closing Remarks

Cheryl Grandinetti, PharmD

Pharmacologist | OSI | FDA

4:10: ADJOURN DAY TWO

4:30 – 5:30 PM: NETWORKING OPPORTUNITY

Onsite attendees are invited to gather at THE HOTEL's Lobby Bar

DAY THREE: Thursday, February 15, 2024

8:30 – 8:45

Day Three Welcome

Forest "Ray" Ford, PharmD, BCPS
Captain | United States Public Health Service (USPHS)
Pharmacist | Small Business and Industry Assistance (SBIA)
 Division of Drug Information (DDI) Office of Communications (OCOMM)
 Center for Drug Evaluation and Research (CDER)

8:45 – 9:00

Opening Remarks & Keynote Address

Seongeun (Julia) Cho, PhD
Division Director | DGDSI | OSIS | FDA

Morning Sessions: Bioequivalence (BE)

9:00 – 9:40

Session 1 (BE) - Remote Evaluations

Moderator: **Sean Kassim, PhD** | OSIS | FDA

- Remote Regulatory Assessments (RRAs) – A valuable tool for OSIS to support drug application review in FDA
- An overview of remote and hybrid Bioequivalence Inspections conducted by the UK MHRA

Mei Ou, PhD
 OSIS | FDA

Michael McGuinness
Head of GLP & Laboratories | Head UK GLPMA | MHRA

9:40 – 10:20

Session 2 (BE) - Bioanalytical Issues

Moderator: **Sean Kassim, PhD** | OSIS | FDA

- Bioanalytical Issues from Recent FDA BIMO Inspections and Remote Regulatory Assessments
- UK MHRA Bioanalytical Observations and Findings from recent Inspections

Yiyue Cynthia Zhang, PhD
 OSIS | FDA

Michael McGuinness
Head of GLP & Laboratories | Head UK GLPMA | MHRA

10:20 – 10:40

Panel Discussion

Moderator: **Sean Kassim, PhD** | OSIS | FDA

10:40 – 11:00: BREAK

DAY THREE: Thursday, February 15, 2024

11:00 – 11:40

Session 3 (BE) - Clinical Study Conduct

Moderator: **Jason Wakelin-Smith** | Expert GCP Inspector and Head of the Compliance Expert Circle | MHRA

- FDA perspectives on Clinical Trial conduct
- MHRA Bioequivalence Inspections- Clinical

Doug Pham, JD, PharmD
OSIS | FDA

Emma Whale, MSc
Senior GCP & GLP Inspector | MHRA

11:40 – 12:00

Panel Discussion (Q&A)

Moderator: **Jason Wakelin-Smith** | Expert GCP Inspector and Head of the Compliance Expert Circle | MHRA

12:00 – 1:00: LUNCH BREAK

Afternoon Sessions: Pharmacovigilance (PV) Compliance

1:00 – 1:15

Pharmacovigilance Compliance Keynote

Stephen Vinter, BSc, CChem
Head of Compliance | Team 1 | MHRA

1:15 – 2:00

Session 4 (PV) - International Collaboration

Moderator: **Carolyn Volpe, PharmD, MS**

- Collaboration with international partners
- How regulatory agencies collaborate to gain an understanding of pharmacovigilance inspections and share information in a global landscape
- Health Canada's Joint Inspection Experience

Claire Longman, MSc
Expert Pharmacovigilance Inspector | MHRA

Sherry Bous, PharmD
Division Director | DEPS | OSI | FDA

Paul Baillargeon
Regulatory Compliance and Enforcement Specialist | HC

2:00 – 3:00

Session 5 (PV) - Future of Inspections

Moderator: **Carolyn Volpe, PharmD, MS**

- FDA's Remote Assessments
- FDA's Office of Regulatory Affairs (ORA) Perspective
- Emerging technologies and related advances in pharmacovigilance

Ginneh Stowe, MS
Health Scientist | FDA Oncology Center of Excellence

Peter Diak, PharmD, MPH
Branch Chief | PSB | DEPS | OSI | FDA

Chrissy Cochran, PhD
Director | OBMO | FDA

Robert Ball, MD, MPH, ScM
Deputy Director | OSE | FDA

3:00 – 3:15: BREAK

DAY THREE: Thursday, February 15, 2024

3:15 – 4:00

Session 6 (PV) - Regulatory Updates

Moderator: **Carolyn Volpe, PharmD, MS**

- FDA Office of Combination Products Part 4 Requirements
- FDA Adverse Event Reporting System (FAERS) Updates
- MHRA Regulatory Updates

Lauren Bateman, MS
Senior Informatics Advisor | OCPP | FDA

Suranjan De, MS, MBA
Deputy Director of the Regulatory Science Staff | OSE | FDA

Claire Longman, MSc
Expert Pharmacovigilance Inspector | MHRA

4:00 – 4:30

Panel Discussion (Q&A)

Moderator: **Carolyn Volpe, PharmD, MS**

4:30 – 4:45

Wrap-up and Closing Remarks

Laurie Muldowney, MD
Deputy Director | OSI | FDA

4:45: ADJOURN WORKSHOP